Human Anti-NCAM1 Recombinant Antibody (clone Promiximab) (CAT#: HPAB-N0187-YC)

Figure 1 Specificity, internalization and affinity of promiximab.

(A) Western blot detected CD56 expression in small cell lung cancer cell lines cell lysates including CD56 extracellular domain (CD56 ECD), NCI-H526, NCI-H524, NCI-H69, NCI-H128, NCI-H446 using promiximab antibody. (B) Western blot was required for detection of CD56 extracellular domain on the condition of deglycosylation or non-deglycosylation using promiximab antibody. (C) Identification of cross reactivity of chimeric antibody with human NK (hNK) cell lysates, human spleen (hSpleen) cell lysates, mouse spleen (mSpleen) cell lysates by western blot, CD56 ECD as control. (D) Binding capacity of promiximab to small cell lung cancer cell lines were detected by flow cytometric analyses and SCLC cell lines incubated with PBS (purple), Promiximab (green), respectively. (E) Internalization of promiximab in CD56-positive small cell lung cancer cell lines were also assessed by flow cytometric analyses, cell lines were incubation with PBS (purple, 4°C, 3 h), promiximab (green, 4°C, 3 h), promiximab (fuchsia, 37°C, 3 h). (F) Biolayer interferometry binding assay were used for monitoring the interaction kinetics between CD56 ECD and different concentrations of promiximab.

Yu, L., Lu, Y., Yao, Y., Liu, Y., Wang, Y., Lai, Q., ... & Yang, J. (2018). Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget, 9(4), 5197.

Figure 2 In vitro cytotoxicity assay of promiximab and promiximab-DUBA.

Small cell lung cancer cell lines and human NK cells were treated with various concentrations of promiximab and promiximab-DUBA for 72 h. The results showed promiximab-DUBA exerted strong inhibitory effects in NCI-H526, NCI-H524 and NCI-H69 cells.

Yu, L., Lu, Y., Yao, Y., Liu, Y., Wang, Y., Lai, Q., ... & Yang, J. (2018). Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget, 9(4), 5197.

Figure 3 Therapeutic effects of promiximab and promiximab-DUBA against NCI-H526 and NCI-H69 small cell lung cancer xenografts.

Promiximab-DUBA showed more powerful inhibition of NCI-H69 or NCI-H526 subcutaneous xenografts growth compared with promiximab, even at lower dose.

Yu, L., Lu, Y., Yao, Y., Liu, Y., Wang, Y., Lai, Q., ... & Yang, J. (2018). Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget, 9(4), 5197.

Figure 4 Histological and pathological observations for mice received multi-dose administration of promiximab or promiximab-DUBA.

Mice were injected with vehicle, 5, and 10 mg/kg of promiximab or promiximab-DUBA. Tissue samples of heart, liver, spleen, lung, and kidney were collected on the day 20 after the last injection. The representative images of heart, liver, spleen, lung, and kidney revealed no visible side toxicities.

Yu, L., Lu, Y., Yao, Y., Liu, Y., Wang, Y., Lai, Q., ... & Yang, J. (2018). Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget, 9(4), 5197.